1-Piperidin-1-yl-pentane-1,3-dione | 73964-87-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-Piperidin-1-yl-pentane-1,3-dione
• 英文别名: 1-Piperidin-1-ylpentane-1,3-dione
• CAS: 73964-87-1
• 化学式: C₁₀H₁₇NO₂
• 分子量: 183.25
• InChiKey: CFILNNVMYGFCKM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  37.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-Piperidin-1-yl-pentane-1,3-dione 、 bis(3-amino-2-pyridyl) diselenide 在 碘 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以86 %的产率得到(Z)-1-(piperidin-1-yl)-2-(1H-pyrido[2,3-b][1,4]selenazin-2(3H)-ylidene)ethan-1-one
  参考文献：
  名称：

  吡啶并/苯并[b][1,4]硒嗪两种异构体的合成：选择性催化剂依赖的 CN 和 C-Se 键的形成

  摘要：

  这项工作描述了通过双(3-氨基-2-吡啶基)或双(2-氨基苯基)二硒化物与不同的β-二羰基化合物的反应选择性合成一系列吡啶并/苯并稠合1,4-硒嗪。当分子I 2用作催化剂时，一系列( Z )-1-(1 H-吡啶并[2,3- b ][1,4]硒嗪-2(3 H )-亚基)丙-2-酮获得。另一方面，在不存在催化剂的情况下，可以选择性地制备1-(2-甲基-1H-吡啶并[2,3- b ][1,4]硒嗪-3-基)乙烷-1-酮。通过NMR和HRMS分析阐明了所制备化合物的结构，并通过单晶X射线衍射证实了其结构。该方案的多功能性不仅通过获得各种 1,4-硒嗪衍生物得到证明，而且还通过 1,3-二羰基前体的结构多样性得到证明，在合成的杂环中结合了多功能性。

  DOI：

  10.1002/adsc.202301003
• 作为产物：
  描述：

  乙腈 以76%的产率得到
  参考文献：
  名称：

  SAITO KIMITOSHI; SATO TADASHI, BULL. CHEM. SOC. JAP., 1979, 52, NO 12, 3601-3605,

  摘要：

  DOI：

文献信息

• C-Met Modulators and Method of Use
  申请人：Bannen Lynne Canne

  公开号：US20110077233A1

  公开（公告）日：2011-03-31

  The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.

  本发明提供了用于调节蛋白激酶酶活性以调节细胞活动（如增殖、分化、程序性细胞死亡、迁移和化学侵袭）的化合物。更具体地，本发明提供了能够抑制、调节和/或调节激酶受体（特别是c-Met、KDF、c-Kit、flt-3和flt-4）信号转导通路的喹唑啉和喹啉，这些信号转导通路与上述细胞活动的变化有关，以及包含这些化合物的组合物和使用它们治疗激酶依赖性疾病和病况的方法。本发明还提供了制备上述化合物的方法和包含这些化合物的组合物。
• c-Met Modulators and Method of Use
  申请人：Exelixis, Inc.

  公开号：US20140155378A9

  公开（公告）日：2014-06-05

  The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.

  本发明提供了用于调节蛋白激酶酶活性以调节细胞活动（如增殖、分化、程序性细胞死亡、迁移和化学入侵）的化合物。更具体地，本发明提供了能够抑制、调节和/或调节激酶受体（特别是c-Met、KDF、c-Kit、flt-3和flt-4）信号转导通路的喹唑啉和喹啉，这些通路与上述细胞活动的变化有关，以及含有这些化合物的组合物和使用它们治疗激酶依赖性疾病和病况的方法。本发明还提供了制备上述化合物的方法和含有这些化合物的组合物。
• C-Met Modulators and Methods of Use
  申请人：Exelixis, Inc.

  公开号：US20150376133A1

  公开（公告）日：2015-12-31

  The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate and/or modulate kinase receptor, particularly c-Met, KDR, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.

  本发明提供了一种调节蛋白激酶酶活性以调节细胞活动（如增殖、分化、程序性细胞死亡、迁移和化学侵袭）的化合物。更具体地，本发明提供了能够抑制、调节和/或调节激酶受体（特别是c-Met、KDR、c-Kit、flt-3和flt-4）信号转导通路，从而影响上述细胞活动变化的喹唑啉和喹啉，以及含有这些化合物的组合物和使用它们治疗激酶依赖性疾病和病况的方法。本发明还提供了制备上述化合物的方法和含有这些化合物的组合物。
• Modulation of Pathogenicity
  申请人：Ammendola Aldo

  公开号：US20070093534A1

  公开（公告）日：2007-04-26

  The present invention relates to the use of compounds of the general Formula (XIII): wherein A 7 is C═O, C═S, SO 2 , CH—OR 13 , C═NR 12 , or CH 2 —CHOR 13 ; A 8 is C(R 14 ) 2 , O, S, or NR 12 ; A 9 is C═O, C═S, SO 2 , CH—OR 13 , C═NR 12 , or CH 2 —CHOR 13 ; m is 0, or 1 q is 0, or 1 r is 0, or 1 R 12 is H, CH 3 , CH 2 —CH 3 , C 6 H 5 , OCH 3 , OCH 2 —CH 3 , OH, or SH; R 13 is H, CH 3 , or CH 2 —CH 3 ; R 14 is H, alkyl, alkoxy, OH, or SH;
• Modulation of pathogenicity
  申请人：Ammendola Aldo

  公开号：US20100280034A1

  公开（公告）日：2010-11-04

  The present invention relates to the use of compounds of the general Formula (XIII): wherein A 7 is C═O, C═S, SO 2 , CH—OR 13 , C═NR 12 , or CH 2 —CHOR 13 ; A 8 is C(R 14 ) 2 , O, S, or NR 12 ; A 9 is C═O, C═S, SO 2 , CH—OR 13 , C═NR 12 , or CH 2 —CHOR 13 ; m is 0, or 1 q is 0, or 1 r is 0, or 1 R 12 is H, CH 3 , CH 2 —CH 3 , C 6 H 5 , OCH 3 , OCH 2 —CH 3 , OH, or SH; R 13 is H, CH 3 , or CH 2 —CH 3 ; R 14 is H, alkyl, alkoxy, OH, or SH;